The financials
Viatris by the numbers
Viatris (VTRS) reported revenue of $3.76B in Q2 2026 (quarter ended June 30, 2026), up 4.9% from the same quarter a year earlier. That came with a gross margin of 39% and net loss of $119M. For the full year FY2025, revenue was $14.3B (−3.0% year on year) and net income −$3.51B. Its largest product in 2026-Q1 was Brands at $1.07B, 30% of the disclosed total, just ahead of Generics at 27%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $3.76B | $3.58B | +4.9% |
| Gross profit | $1.46B | $1.33B | +9.3% |
| Operating income | $6.3M | $233M | −97% |
| Net income | −$119M | −$4.6M | n/a |
| Diluted EPS | −$0.10 | $0.00 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Brands | $1.07B | 30% |
| Generics | $952M | 27% |
| Lipitor | $462M | 13% |
| Norvasc | $210M | 6.0% |
| Lyrica | $121M | 3.4% |
| Epi Pen Auto Injectors | $101M | 2.9% |
| Creon | $97M | 2.8% |
| Viagra | $95M | 2.7% |
| Zoloft | $73M | 2.1% |
| Celebrex | $67M | 1.9% |
| Yupelri | $63M | 1.8% |
| Effexor | $62M | 1.8% |
| Xalabrands | $39M | 1.1% |
| Dymista | $37M | 1.1% |
| Xanax | $35M | 1.0% |
| Amitiza | $34M | 1.0% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $3.52B (-9.0%)
Norvasc grew +22% year on yearDymista -13% year on year
Segment Latestquarter on quarteryear on year
- Brands$1.07B$1.07BQoQ -14%year on year +4.8%-14%+4.8%
- Generics$951.8M$951.8MQoQ -6.2%year on year +9.2%-6.2%+9.2%
- Lipitor$462.0M$462.0MQoQ +17%year on year +19%+17%+19%
- Norvasc$210.0M$210.0MQoQ +17%year on year +22%+17%+22%
- Lyrica$120.6M$120.6MQoQ -4.7%year on year +7.1%-4.7%+7.1%
- Epi Pen Auto Injectors$101.1M$101.1MQoQ -36%year on year +4.6%-36%+4.6%
- Creon$97.4M$97.4MQoQ +4.6%year on year +18%+4.6%+18%
- Viagra$95.0M$95.0MQoQ -9.7%year on year -3.6%-9.7%-3.6%
- Zoloft$72.6M$72.6MQoQ +8.7%year on year +21%+8.7%+21%
- Celebrex$67.1M$67.1MQoQ -8.5%year on year +5.8%-8.5%+5.8%
- Yupelri$62.5M$62.5MQoQ -12%year on year +7.2%-12%+7.2%
- Effexor$62.0M$62.0MQoQ -7.7%year on year +4.6%-7.7%+4.6%
- Xalabrands$39.2M$39.2MQoQ +1.6%year on year +5.7%+1.6%+5.7%
- Dymista$37.3M$37.3MQoQ +10%year on year -13%+10%-13%
- Xanax$34.8M$34.8MQoQ +1.8%year on year +7.7%+1.8%+7.7%
- Amitiza$34.0M$34.0MQoQ -17%year on year +2.1%-17%+2.1%
- Influvac--QoQ -year on year ---
Drug Manufacturers - Specialty & Generic
Ranks #7 of 28 by Smart Score